ovarian-cancer

Documents about ovarian-cancer

• Japan Phase 2 Study of Niraparib in Participants With Advanced, Relapsed Ovarian Cancer#828427ClinicalTrials.gov
• CONTIGO - A Narrative Intervention to Enhance Genetic Counseling and Testing#837885ClinicalTrials.gov
• Multi-Centre Observational Study of Maintenance Niraparib in Treatment of Ovarian CanceR#871158ClinicalTrials.gov
• Nab-Sirolimus and Endocrine Therapy in Recurrent Low Grade Serous Ovarian Cancer (NARETO)#863147ClinicalTrials.gov
• Prospective Study of Immune Alterations in Operable Breast and Ovarian Carcinoma#908988ClinicalTrials.gov
• A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ®) in Patients With Ovarian Cancer and Selected Solid Tumors#807021ClinicalTrials.gov
• Search Allelic Imbalance of Expression of BRCA Genes in Hereditary Risk of Breast and/or Ovarian Cancer#881057ClinicalTrials.gov
• Activated T-cell Therapy, Low-Dose Aldesleukin, and Sargramostim in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That is Stage III-IV, Refractory, or Recurrent#872646ClinicalTrials.gov
• Monoclonal Antibody Vaccine Therapy in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer#160182ClinicalTrials.gov
• Study of DPX-Survivac Therapy in Patients With Recurrent Ovarian Cancer#195330ClinicalTrials.gov
• Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Women With Suspected Ovarian or Endometrial Cancer#873109ClinicalTrials.gov
• Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer#857966ClinicalTrials.gov
• Chemotherapy Combined With Propranolol Hydrochloride as Neoadjuvant Therapy for Advanced High-grade Serous Ovarian Cancer#67897ClinicalTrials.gov
• Study of Metformin With Carboplatin/Paclitaxel Chemotherapy in Patients With Advanced Ovarian Cancer#180282ClinicalTrials.gov
• A Clinical Study on Fasudil Hydrochloride for Treatment of Gene-Specific Ovarian Cancer#217039ClinicalTrials.gov
• INOVATYON STUDY -International, Randomized Study in Patients With Ovarian Cancer#811567ClinicalTrials.gov
• A Study of DMOT4039A in Participants With Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer#813170ClinicalTrials.gov
• Sentinel Lymph Node in Early Ovarian Cancer#825152ClinicalTrials.gov
• Adoptive T Cell Therapy in Patients With Recurrent Ovarian Cancer#833262ClinicalTrials.gov
• EP-100 Plus Paclitaxel Versus Paclitaxel Alone in Patients With Ovarian Cancer#862839ClinicalTrials.gov
• Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian Cancer#891704ClinicalTrials.gov
• Pembrolizumab and Lenvatinib in Clear Cell Ovarian Cancer#912142ClinicalTrials.gov
• miRNAs in High Grade Serous Ovarian Cancer#916230ClinicalTrials.gov
• Multicenter Clinical Trial of Intravenous OvaRex MAb-B43.13 as Post-Chemotherapy Consolidation for Ovarian Carcinoma#851165ClinicalTrials.gov
• Lavage of the Uterine Cavity for the Diagnosis of Ovarian and Tubal Carcinoma - Study of Sensitivity and Specificity#859506ClinicalTrials.gov
• Interleukin-12 in Treating Patients With Refractory Advanced-Stage Ovarian Cancer or Abdominal Cancer#891532ClinicalTrials.gov
• DCVAC/OvCa After Standard-of-care Chemotherapy in Women With Relapse of Platinum-sensitive Epithelial Ovarian Cancer#891291ClinicalTrials.gov
• Abraxane/Bevacizumab#877160ClinicalTrials.gov
• PEG-Interferon Alfa-2b in Treating Patients With Platinum-Resistant Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer#234506ClinicalTrials.gov
• Sequential EHR Based Interventions to Increase Genetic Testing for Breast and Ovarian Cancer Predisposition#862877ClinicalTrials.gov
• Imaging of Peritoneal Carcinomatosis From Ovarian Carcinoma Patients#881985ClinicalTrials.gov
• Irofulven in Treating Patients With Recurrent or Persistent Ovarian Epithelial or Primary Peritoneal Cancer#804037ClinicalTrials.gov
• Platinum-based Chemotherapy With Atezolizumab and Niraparib in Patients With Recurrent Ovarian Cancer#904817ClinicalTrials.gov
• Using Advanced Imaging Studies to Develop a Profile of High-grade Serous Ovarian Cancer#843064ClinicalTrials.gov
• Trial of M4344 and Niraparib in Patients With Poly (ADP-ribose) Polymerase (PARP) Resistant Recurrent Ovarian Cancer#891484ClinicalTrials.gov
• Phase Ib/IIa Trial to Evaluate Oregovomab and Nivolumab in Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin#146445ClinicalTrials.gov
• Evaluation of Fluciclovine Uptake in Patients With Cervical, Ovarian Epithelial or Endometrial Cancers.#869475ClinicalTrials.gov
• A Trial Using Novel Markers to Predict Malignancy in Elevated-Risk Women#872302ClinicalTrials.gov
• Ribociclib (Ribociclib (LEE-011)) With Platinum-based Chemotherapy in Recurrent Platinum Sensitive Ovarian Cancer#887716ClinicalTrials.gov
• Psychosexual Intervention in Patients With Stage I-III Gynecologic or Breast Cancer#841592ClinicalTrials.gov
• Carboplatin, Gemcitabine Hydrochloride, and Berzosertib in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer#826940ClinicalTrials.gov
• Identifying the best diagnostic test for ovarian cancer – synopsis of Refining Ovarian Cancer Test accuracy Scores (ROCkeTS) research#1752NCBI Bookshelf
• Iparomlimab and Tuvonralimab Plus Chemotherapy as Neoadjuvant Therapy for Ovarian Cancer（Phase II）#325285ClinicalTrials.gov
• <b>Multi-Class Ovarian Cancer Subtype Classification</b>#361729Figshare
• A Study of Pembrolizumab With Standard Treatment in Patients With Recurrent Platinum-resistant Ovarian Cancer#373598ClinicalTrials.gov
• Fragmin in Ovarian Cancer: Utility on Survival (FOCUS)#829682ClinicalTrials.gov
• Efficacy and Safety Study of Sorafenib With Topotecan in Patients With Platinum-resistant Recurrent Ovarian Cancer#847783ClinicalTrials.gov
• Combination Therapy for Recurrent Ovarian Cancer#862994ClinicalTrials.gov
• Ovarian Cancer Risk Estimation in Patients With Pelvic Mass#871974ClinicalTrials.gov
• Use of New MolEcular MarkErs for a persoNalized Therapy in Ovarian Cancer-MEMENTO#875125ClinicalTrials.gov